Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4085-4090

  Kim, Doyeob ^a   Lee, Il Sun ^a   Jung, Ji Hyung ^b   Lee, Chong Ock ^a   Choi, Sang Un ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Multidurg resistance; P glycoprotein; Psammaplin A; Topoisomerase II

Indexed keywords

DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; PHENOL DERIVATIVE; PSAMMAPLIN A; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; AMSACRINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; DISULFIDES; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; INHIBITORY CONCENTRATION 50; MITOXANTRONE; NUCLEIC ACID CONFORMATION; PHENYLPROPIONATES; TUMOR CELLS, CULTURED; TYROSINE; VERAPAMIL;

EID: 0032806308     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Osheroff N, Zechiedrich E and Gale KC: Catalytic function of DNA topoisomerase II. Bioassays 13: 269-275, 1991.
2. Cummings J and Smyth JF: DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533-543, 1993.
3. Tewey KM, Chen GL, Nelson EM, Liu LF: Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 9182-9187, 1984.
4. Lum BL, Gosland MP, Kauhisch S and Sikic BI: Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacotherapy 13: 88-109, 1993.
5. Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36: 161-183, 1996.
6. Endicott JA and Ling V: The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
7. Jung JH, Sim CJ and Lee CO: Cytotoxic compounds from a two-sponge association. J Nat Prod 58: 1722-1726, 1995.
8. Osheroff N, Shelton ER and Brutlag DL: DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem 258: 9536-9543, 1983.
9. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA and Osheroff N: Effects of quinolone derivatives on eucaryotic topoisomerase II. J Biol Chem 266: 14585-14592, 1991.
10. Sahai BM and Kaplan JG: A quantitative decatenation assay for type II topoisomerases. Anal Biochem 156: 364-379, 1986.
11. Hasinoff BB, Creighton AM, Kozlowska H, Thampatty P, Allan WP and Yalowich JC: Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts as the hisdioxopiperazine binding site. Mol Pharmacol 52: 839-845, 1997.
12. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD and Tew KD: P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine, J Natl Cancer Inst 86: 688-694, 1994.
13. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT and Bates SE: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46: 627-638. 1994.
14. Choi S-U, Kim NY, Choi EJ, Kim KH, Lee JO: Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells. Arch Pharm Res 19: 342-347, 1996.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
16. Choi S-U, Lee C-O, Kim K-H, Choi E-J, Park S-H, Shin H-S, Yoo S-E, Jung N-P and Lee B-H: Reversal of multidrug resistance by novel verapamil analogs in cancer cells. Anti-Cancer Drugs 9: 157-165, 1998.
17. Quinoa E and Crews P: Phenolic constituents of Psammaplysilla. Tetrahedron Lett 28: 3229-3232, 1987.
18. Alvarez M, Raull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates SE and Fojo AT: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Invest 95: 2205-2214, 1995.
19. Chan HS, Thorner PS, Haddad G and Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 50: 2818-2822, 1990.
20. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yegar H and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
21. Choi S-U, Park S-H, Kim K-H, Choi E-J, Kim S, Park W-K, Zhang Y-H, Kim H-S, Jung N-P and Lee C-O: The bisbenzylisoquinoline alkaloids, tetrandrine and fangchinoline enhance the cytotoxicity of MDR-related drugs via modulation of Pgp. Anticancer Drugs 9: 255-261, 1998.
22. Tsuruo J, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhancing cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
23. Iwahashi T, Okochi E, Ono K, Sugawara I, Tsuruo T and Mori S: Establishment of multidrug resistant human colorectal carcinoma HCT15 cell lines and their properties. Anticancer Res 11: 1309-1312, 1991.